Asthika Goonewardene
Stock Analyst at Truist Securities
(2.19)
# 2,890
Out of 5,090 analysts
96
Total ratings
40.66%
Success rate
-2.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $24.21 | +77.61% | 1 | Nov 25, 2025 | |
| MRSN Mersana Therapeutics | Downgrades: Hold | $36 → $31 | $27.42 | +12.14% | 6 | Nov 13, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $32.03 | +49.86% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $122.42 | +18.44% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $25.26 | +54.39% | 2 | Oct 7, 2025 | |
| MRUS Merus | Downgrades: Hold | $88 → $97 | $96.20 | +0.83% | 3 | Sep 29, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $16.38 | +510.50% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $78.51 | +26.11% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $44.40 | +10.37% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $95.99 | +61.48% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $27.87 | +154.75% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $1.45 | +592.04% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.57 | +536.94% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $2.22 | +575.68% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.83 | +85.92% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $136 | $68.14 | +99.60% | 5 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $8.81 | +1,602.61% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.59 | +151.57% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.94 | +881.91% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.56 | +4,681.30% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $11.37 | +955.41% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.97 | +2,945.69% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $12.93 | +1,292.11% | 4 | Aug 23, 2022 |
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $24.21
Upside: +77.61%
Mersana Therapeutics
Nov 13, 2025
Downgrades: Hold
Price Target: $36 → $31
Current: $27.42
Upside: +12.14%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $32.03
Upside: +49.86%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $122.42
Upside: +18.44%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $25.26
Upside: +54.39%
Merus
Sep 29, 2025
Downgrades: Hold
Price Target: $88 → $97
Current: $96.20
Upside: +0.83%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $16.38
Upside: +510.50%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $78.51
Upside: +26.11%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $44.40
Upside: +10.37%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $95.99
Upside: +61.48%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $27.87
Upside: +154.75%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $1.45
Upside: +592.04%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.57
Upside: +536.94%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $2.22
Upside: +575.68%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $18.83
Upside: +85.92%
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $68.14
Upside: +99.60%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $8.81
Upside: +1,602.61%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.59
Upside: +151.57%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.94
Upside: +881.91%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.56
Upside: +4,681.30%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $11.37
Upside: +955.41%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.97
Upside: +2,945.69%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $12.93
Upside: +1,292.11%